Random splicing of several exons caused by a single base change in the target exon of CRISPR/cas9 mediated gene knockout

Cells

Volumn 5, Issue 4, 2016, Pages

  Kapahnke, Marcel ^a   Banning, Antje ^a   Tikkanen, Ritva ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Cas9; CRISPR; Flotillin; Genome editing; RNA splicing

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CRISPR ASSOCIATED PROTEIN; FLOTILLIN 1; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CRISPR CAS SYSTEM; DNA REPAIR; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; WESTERN BLOTTING;

EID: 85056746537     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells5040045     Document Type: Article

References (24)

1. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNAguided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816–821. [PubMed]
2. Ran, F.A.; Hsu, P.D.; Wright, J.; Agarwala, V.; Scott, D.A.; Zhang, F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013, 8, 2281–2308. [PubMed]
3. Banning, A.; Kurrle, N.; Meister, M.; Tikkanen, R. Flotillins in receptor tyrosine kinase signaling and cancer. Cells 2014, 3, 129–149. [PubMed]
4. Meister, M.; Tomasovic, A.; Banning, A.; Tikkanen, R. Mitogen-activated protein (MAP) kinase scaffolding proteins: A recount. Int. J. Mol. Sci. 2013, 14, 4854–4884. [PubMed]
5. Amaddii, M.; Meister, M.; Banning, A.; Tomasovic, A.; Mooz, J.; Rajalingam, K.; Tikkanen, R. Flotillin-1/ reggie-2 protein plays dual role in activation of receptor-tyrosine kinase/mitogen-activated protein kinase signaling. J. Biol. Chem. 2012, 287, 7265–7278. [PubMed]
6. Banning, A.; Ockenga, W.; Finger, F.; Siebrasse, P.; Tikkanen, R. Transcriptional regulation of flotillins by the extracellularly regulated kinases and retinoid X receptor complexes. PLoS ONE 2012, 7, e45514. [CrossRef] [PubMed]
7. Kuhne, S.; Ockenga, W.; Banning, A.; Tikkanen, R. Cholinergic Transactivation of the EGFR in HaCaT Keratinocytes Stimulates a Flotillin-1 Dependent MAPK-Mediated Transcriptional Response. Int. J. Mol. Sci. 2015, 16, 6447–6463. [CrossRef] [PubMed]
8. Edgar, A.J.; Polak, J.M. Flotillin-1: Gene structure: cDNA cloning from human lung and the identification of alternative polyadenylation signals. Int. J. Biochem. Cell Biol. 2001, 33, 53–64. [CrossRef]
9. Kurrle, N.; Vollner, F.; Eming, R.; Hertl, M.; Banning, A.; Tikkanen, R. Flotillins directly interact with gamma-catenin and regulate epithelial cell-cell adhesion. PLoS ONE 2013, 8, e84393. [CrossRef] [PubMed]
10. Vollner, F.; Ali, J.; Kurrle, N.; Exner, Y.; Eming, R.; Hertl, M.; Banning, A.; Tikkanen, R. Loss of flotillin expression results in weakened desmosomal adhesion and Pemphigus vulgaris-like localisation of desmoglein-3 in human keratinocytes. Sci. Rep. 2016, 6, 28820. [CrossRef] [PubMed]
11. Banning, A.; Gulec, C.; Rouvinen, J.; Gray, S.J.; Tikkanen, R. Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria. Sci. Rep. 2016, 6, 37583. [CrossRef] [PubMed]
12. Saarela, J.; Laine, M.; Oinonen, C.; von Schantz, C.; Jalanko, A.; Rouvinen, J.; Peltonen, L. Molecular pathogenesis of a disease: Structural consequences of aspartylglucosaminuria mutations. Hum. Mol. Genet. 2001, 10, 983–995. [CrossRef] [PubMed]
13. Heckl, D.; Charpentier, E. Toward whole-transcriptome editing with CRISPR-Cas 9. Mol. Cell 2015, 58, 560–562. [CrossRef] [PubMed]
14. Bosley, K.S.; Botchan, M.; Bredenoord, A.L.; Carroll, D.; Charo, R.A.; Charpentier, E.; Cohen, R.; Corn, J.; Doudna, J.; Feng, G. et al. CRISPR germline engineering–the community speaks. Nat. Biotechnol. 2015, 33, 478–486. [CrossRef] [PubMed]
15. Charpentier, E. CRISPR-Cas9: How research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine. EMBO Mol. Med. 2015, 7, 363–365. [CrossRef] [PubMed]
16. Sander, J.D.; Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014, 32, 347–355. [CrossRef] [PubMed]
17. Schwank, G.; Koo, B.K.; Sasselli, V.; Dekkers, J.F.; Heo, I.; Demircan, T.; Sasaki, N.; Boymans, S.; Cuppen, E.; van der Ent, C.K. et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013, 13, 653–658. [CrossRef] [PubMed]
18. Lee, Y.; Rio, D.C.: Mechanisms and regulation of alternative pre-mRNA splicing. Annu. Rev. Biochem. 2015, 84, 291–323. [CrossRef] [PubMed]
19. Scotti, M.M.; Swanson, M.S. RNA mis-splicing in disease. Nat. Rev. Genet. 2016, 17, 19–32. [CrossRef] [PubMed]
20. Disset, A.; Bourgeois, C.F.; Benmalek, N.; Claustres, M.; Stevenin, J.; Tuffery-Giraud, S. An exon skippingassociated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum. Mol. Genet. 2006, 15, 999–1013. [CrossRef] [PubMed]
21. Korvatska, O.; Strand, N.S.; Berndt, J.D.; Strovas, T.; Chen, D.H.; Leverenz, J.B.; Kiianitsa, K.; Mata, I.F.; Karakoc, E.; Greenup, J.L. et al. Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum. Mol. Genet. 2013, 22, 3259–3268. [CrossRef] [PubMed]
22. Miller, J.N.; Pearce, D.A. Nonsense-mediated decay in genetic disease: Friend or foe? Mutat. Res. Rev. Mutat. Res. 2014, 762, 52–64. [CrossRef] [PubMed]
23. Morrow, I.C.; Rea, S.; Martin, S.; Prior, I.A.; Prohaska, R.; Hancock, J.F.; James, D.E.; Parton, R.G. Flotillin-1/reggie-2 traffics to surface raft domains via a novel golgi-independent pathway. Identification of a novel membrane targeting domain and a role for palmitoylation. J. Biol. Chem. 2002, 277, 48834–48841. [CrossRef] [PubMed]
24. Liu, J.; Deyoung, S.M.; Zhang, M.; Dold, L.H.; Saltiel, A.R. The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280, 16125–16134. [CrossRef] [PubMed]